Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
If a treatment is not effective - we dont offer it
Clinical efficacy studies of various unimolecular dual and triple agonists targeting the GLP- 1 receptor, GIP receptor, and glucagon receptor have shown promising results when used alone or in conjunction with approved hypoglycemic medications
Shima Hadidchi Primary Care, we have a team of medical professionals dedicated to providing personalized and comprehensive care to our patients
This triple mechanism distinguishes it from existing approved treatments such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
It usually results in mild and self-limited central nervous system (CNS) depression
Blood sugar control In the SURPASS-2 head-to-head trial (NCT03987919), tirzepatide reduced HbA1c by up to 2.30%, compared with 1.86% for semaglutide
US$ 28.02
US$ 21.62
US$ 24.91
US$ 22.66
US$ 29.10
